欧洲电子临床结果评估 (eCOA) 市场 – 行业趋势和 2030 年预测

欧洲电子临床结果评估 (eCOA) 市场分析和规模

临床试验数量的增加、提高合规性的需求、有效获取和管理临床信息、降低成本以及增加研发活动预计将推动市场增长。Kayentis 是一家专门从事电子临床结果评估 (eCOA) 解决方案的法国公司，将于 2020 年 12 月获得约 830 万美元的资金。这有助于其实现区域扩张和产品开发的目标。

Data Bridge Market Research 分析，电子临床结果评估 (eCOA) 市场在 2022 年的规模为 14.2 亿美元，预计到 2030 年将达到 47.5 亿美元，在 2022 年至 2030 年的预测期内的复合年增长率为 16.30%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

欧洲电子临床结果评估 (eCOA) 市场范围和细分

Market Definition

Electronic clinical outcome assessment (eCOA) is a system capable of measuring mental state, patient symptoms, and disease prognosis. The electronic clinical outcome assessments enable real-time visibility, which helps in enhancing protocol adherence, assuring patient safety and participation, and lowering trial risks. The state of a patient, as well as the consequences and course of a disease, are determined via electronic clinical outcome assessments (eCOA). Electronic diaries and electronic Patient Reported Outcomes are important components of eCOA platforms. These components serve as ePRO support systems.

Europe Clinical Outcome Assessment (eCOA) Market Dynamics

Drivers

• Rising burden on pharmaceutical manufacturers

New medication development techniques are increasingly relying on electronic data capture rather than paper-based procedures to reduce total costs. Data collection using electronic clinical outcome assessment platforms improves data quality, harmonises data collection practises, and provides significant value to its users, such as data analysis. Electronic data collection and analysis services eliminate paper-based records' drawbacks while increasing patient compliance. They also reduce the cost of site monitoring and eliminate the risk of data fluctuation. These solutions provide streamlined information, which helps to improve data quality by gathering data in a structured manner. The above-mentioned benefits of using electronic clinical outcome assessments are expected to boost product demand.

• Rise in clinical outcome assessments

Clinical outcome assessments (COAs) are thus being used more frequently to assess the efficacy of various chronic illness therapies. These have frequently been crucial in the regulatory approval of medicines. The addition of numerous services will also help it grow. For instance, in June 2021, Signant Health launched a novel acceleration programme that reduces study setup timelines by 50% or more without compromising clinical data quality. Thus, the increasing launch of novel programmes that benefit companies in assessing clinical trial studies is likely to increase demand for electronic clinical outcome assessment solutions, thereby boosting market growth.

Opportunities

• Rising demand for electronic clinical outcome assessment solutions

According to a study published in the American Chemical Society Pharmacology and Translational Science, 2020, new potential therapeutics for COVID-19 identified with a combined virtual and experimental screening strategy and chosen from a library of nearly 4,000 approved drugs with hydroxychloroquine (HCQ) as a reference drug were studied to screen for structural similarity against a library of almost 4,000 approved drugs with hydroxychloroquine (HCQ) as a reference drug. The study proposed zuclopenthixol, nebivolol, and amodiaquine as potential clinical trial candidates against the early stage of SARS-CoV-2 infection and remdesivir and favipiravir therapeutics as potential adjuvants in COVID-19 treatment. As a result of the increased number of clinical trials due to the repurposing of several medicines, the demand for electronic clinical outcome assessment solutions is expected to rise.

Restraints/Challenges

• High implementation costs

Data privacy issues and expensive implementation costs limit the market's expansion. Furthermore, the market is expected to be challenged by a lack of favourable reimbursement scenarios in developing economies, high custom duty imposed on medical equipment, and a lack of sufficient infrastructure in low- and middle-income nations during the forecast period of 2023-2030.

This electronic clinical outcome assessment (eCOA) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the electronic clinical outcome assessment (eCOA) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Electronic Clinical Outcome Assessment (eCOA) Market

The COVID-19 pandemic hampered clinical study conduct and management in 2020. To address these issues and ensure the continuity of clinical research activities, market participants implemented various initiatives, including eClinical technologies. As a result of the pandemic, clinical trials were digitized. Many sponsors, biopharma companies, medical device companies, and contract research organisations (CROs) have begun using eClinical systems to collect, manage, and derive meaningful insights from data cost-effectively and remotely. With the help of electronic clinical outcome assessment, patient data can be collected remotely (eCOA).

持续的 COVID-19 疫情是一场历史性的健康威胁，正在给世界各地的社区、行业、企业和人民带来严重破坏。COVID-19 的直接潜在影响已导致数百万人丧生，医疗成本大幅增加。医疗监测和安全报告至关重要，因为多种潜在药物在疫苗研发之前进行了测试，并且也用于治疗冠状病毒引起的感染。因此，对电子临床结果评估解决方案的需求有所增加，预计在不久的将来会进一步增加。

近期发展

• 2020 年，甲骨文将其云系统扩展到澳大利亚（墨尔本）、日本（大阪）、沙特阿拉伯（吉达）、荷兰（阿姆斯特丹）和加拿大（蒙特利尔）。市场扩张预计将受益于消费者对其基于云的应用程序的认知度提高。

• 2020 年，ArisGlobal 与 Soterius, Inc. 合作，通过在其面向服务的技术堆栈中添加 LifeSphere Medical Information 和 LifeSphere MultiVigilance 来扩展其产品供应。

欧洲电子临床结果评估 (eCOA) 市场范围

电子临床结果评估 (eCOA) 市场根据产品、交付模式、方法、平台和最终用户进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

产品

• 本地解决方案
• 基于云的解决方案
• 基于 Web 的解决方案

交付方式

• 网站托管
• 基于云

方法

• 患者报告结果 (PRO)
• 临床医生报告结果 (CLINRO)
• 观察者报告结果 (OBSRO)
• 绩效结果（PERFO）

平台

• 合同研究组织
• 制药和生物制药公司
• 医疗器械制造商
• 医院和临床实验室
• 咨询服务公司
• 研究与学术
• 其他的

终端用户

• 制药和生物制药公司
• 合同研究组织
• 其他最终用户

电子临床结果评估 (eCOA) 市场区域分析/见解

对电子临床结果评估 (eCOA) 市场进行了分析，并按国家、产品、交付模式、方法、平台和最终用户提供了市场规模洞察和趋势。

电子临床结果评估 (eCOA) 市场报告涵盖的国家包括欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其和欧洲其他地区。

由于德国各国当局和协会为加强临床试验做出了巨大努力，德国电子临床结果评估 (eCOA) 市场正在不断增长。 

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

医疗保健基础设施增长安装基础和新技术渗透

电子临床结果评估 (eCOA) 市场还为您提供每个国家/地区资本设备医疗保健支出增长、电子临床结果评估 (eCOA) 市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗保健监管情景的变化及其对电子临床结果评估 (eCOA) 市场的影响的详细市场分析。数据适用于 2011-2021 年的历史时期。

竞争格局和电子临床结果评估 (eCOA) 市场份额分析

电子临床结果评估 (eCOA) 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对电子临床结果评估 (eCOA) 市场的关注有关。

电子临床结果评估 (eCOA) 市场的一些主要参与者包括：

• IBM 公司（美国）
• IQVIA（美国）
• Medidata Solutions, Inc.（美国）
• Clario (美国)
• ArisGlobal (美国)
• Signant Health（美国）
• TransPerfect（美国）
• Cloudbyz（美国）
• Climedo Health GmbH（德国）
• ClinCapture（美国）
• 甲骨文公司（美国）
• Paraxel International Corporation（美国）
• eClinical Solutions LLC（美国）
• OmniComm Systems, Inc.（美国）
• CRF Health（美国）
• 欧洲圆桌会议（美国）

SKU-52428